Plus TherapeuticsPSTV -4.37%26 9-Day RSI is 34.39 as of Jul. 01, 2026. GuruFocus rates PSTV with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Plus Therapeutics ranks better than 76.23% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Plus Therapeutics's 9-Day RSI or its related term are showing as below:
PSTV's 9-Day RSI is ranked better than 76.23% of 1422
companies
in the Biotechnology industry
Industry Median: 49.72
vs PSTV: 34.39
Plus Therapeutics (NAS:PSTV) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Plus Therapeutics 9-Day RSI Related Terms
PSTV vs KYNB, VTGN, TVGN: 9-Day RSI Comparison
For the Biotechnology subindustry, Plus Therapeutics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's 9-Day RSI falls into.
Plus Therapeutics (NAS:PSTV) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics (PSTV) has a 9-Day RSI of 34.39 as of Jul. 01, 2026. According to the industry distribution chart, Plus Therapeutics ranks #338 out of 1422 companies in the Biotechnology industry, placing it in the top 23.8%.
Is Plus Therapeutics' 9-Day RSI too high?
Plus Therapeutics' current 9-Day RSI is 34.39. The Biotechnology industry median 9-Day RSI is 49.72. Plus Therapeutics' value of 34.39 is 30.8% below this industry median. Based on the distribution chart, Plus Therapeutics ranks #338 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Plus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' 9-Day RSI compare to KYNB and VTGN?
According to the Biotechnology industry distribution chart, Plus Therapeutics ranks #338 out of 1422 companies for 9-Day RSI. This places Plus Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 49.72. Plus Therapeutics' value of 34.39 is 30.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 49.72, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Plus Therapeutics's current 9-Day RSI of 34.39 is 30.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 49.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plus Therapeutics's current 9-Day RSI is 34.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current 9-Day RSI of 34.39. The current 9-Day RSI is 34.39 and 30.8% below the Biotechnology industry median of 49.72. Plus Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current 9-Day RSI is 34.39 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
26GF Score
Get the complete analysis for PSTV
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSTV has been successfully added to your 